JPOST Repositoryapplication/xmlhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e1-1_1st_02.rawhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e1-2_1st_01.rawhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e2-2_1st_01.rawhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e2-2_2nd+3rd_02.rawhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e2-1_2nd+3rd_01.rawhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e1-2_2nd+3rd_01.rawhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e1-1_2nd+3rd_02.rawhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e2-1_1st_02.rawhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e2-2_2nd+3rd_01.rawhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e1-2_1st_02.rawhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e2-1_1st_01.rawhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e1-1_1st_01.rawhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e2-2_1st_02.rawhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e2-1_2nd+3rd_02.rawhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e1-2_2nd+3rd_02.rawhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e1-1_2nd+3rd_01.rawhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e2-2_2tech_merge.mgfhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e1-1_2tech_merge.mgfhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e1-2_2tech_merge.mgfhttps://storage.jpostdb.org/JPST001225/files/20170405_QE1_sand_AcOH_PE_2017-49_SIMAC_e2-1_2tech_merge.mgfprimaryOK200ProteomicsToshinori KinoshitaCellular Organismshttps://repository.jpostdb.org/entry/JPST001225Nagoya UniversityjPOST14 3 3 beta Protein, Brain, (+)-(S)-ABA, global chromatin profiling, GOLIM1, zeta Isoform, Vetchs, epsilon Isoform, 4-trans-abscisic acid, (7E, Abscisic acid, 14 3 3zeta Protein, (S)-(+)-abscisic acid, 14-3-3tau Protein, fam:14-3-3, tau Isoform, 14-3-3gamma Protein, GCP372, 14 3 3beta Protein, 9Z)-(6S)-6-hydroxy-3-oxo-11-apo-epsilon-caroten-11-oic acid., Protein, 14 3 3 epsilon Protein, global chromatin epigenetic profiling, 14-3-3tau, 14 3 3gamma Protein, 14-3-3eta Protein, eta Protein, 14-3-3 epsilon Protein, beta Isoform, Protein 14-3-3, 14 3 3 zeta Protein, gamma Isoform, ABA, Vetch, Brain 14-3-3 Protein, 14 3 3 tau Protein, COD5, 14 3 3eta Protein, CBD, granule cell progenitor, 14 3 3epsilon Protein, 14-3-3epsilon Protein, 14-3-3 gamma Protein, 14 3 3 Proteins, 14-3-3 eta Protein, 14 3 3 Protein, Vicias, eta Isoform, 14-3-3beta Protein, 14-3-3, 14-3-3zeta Protein, 2-cis, Brain 14 3 3 Protein, GOP, 14-3-3 Protein, 14-3-3 beta Protein, (+)-S-ABA, 14 3 3 gamma Protein, OPN1MW1, granule cell precursor, 14 3 3 eta Protein, Gcp, GCP, CBBM, 14 3 3tau Protein, 14-3-3 tau Protein, 14-3-3 zeta Protein, abscisin II14 3 3 beta Protein, Brain, Hac-1/Dark, Co-Immunoprecipitations, Dapaf-1/HAC-1, DmelCG6829, zeta Isoform, (7E, B-cell receptor complex, Apaf-1, (S)-(+)-abscisic acid, 14-3-3tau Protein, fam:14-3-3, polysyndactyly with peculiar skull Shape, CG7826, Co Immunoprecipitation, tau Isoform, Dark/Hac-1/dApaf1, antibody, Hac1, BCR complex, Dark/Hac-1/dApaf-1, 14 3 3beta Protein, Immune Precipitations, CG7835, 14-3-3tau, CG42273, 14 3 3gamma Protein, Min, Apaf1, ACLS, 14-3-3 epsilon Protein, immunoglobulin complex, ARK, Immune Precipitation, DmelCG42273, 14 3 3 zeta Protein, ABA, Vetch, 14 3 3 tau Protein, 14 3 3epsilon Protein, PAPA1, hac-1, 14-3-3epsilon Protein, 14-3-3 gamma Protein, membrane bound, Co-Immunoprecipitation, dapaf-1, Precipitation, min, arc, mAPC, dapaf, dark, PHS, ark, T1, 14-3-3beta Protein, AI047805, 2-cis, Immune, DARK, (+)-S-ABA, dApaf1, 14 3 3tau Protein, Precipitations, B-lymphocyte receptor complex, dArk, Dapaf-1, 14-3-3 tau Protein, 14-3-3 zeta Protein, dark/dapaf-1/hac-1, DYRK1, (+)-(S)-ABA, PAPB, PAPA, D-Apaf-1, dApaf-1, Vetchs, epsilon Isoform, anon-53Fa, 4-trans-abscisic acid, Dmel_CG7826, 9Z)-(6S)-6-hydroxy-3-oxo-11-apo-epsilon-caroten-11-oic acid, l(2)SH0173, apaf1, Abscisic acid, 14 3 3zeta Protein, antibodies, 14-3-3gamma Protein, APAF1, GLI3-190, Dm1, Hac-1, Protein, 14 3 3 epsilon Protein, 14-3-3eta Protein, Dyrk1, Dark, eta Protein, Dark/Apaf-I, CG6829, Dmel_CG7835, beta Isoform, Protein 14-3-3, gamma Isoform, opsonin activity, Mnb, MNB, AU020952, Brain 14-3-3 Protein, 14 3 3eta Protein, Greig syndrome, GLI3FL, 14 3 3 Proteins, CC1, 14-3-3 eta Protein, 14 3 3 Protein, Dark/Dapaf-1/HAC1, hac1, AW124434, dark/hac-1/dapaf-1., Vicias, dApaf-1/DARK/HAC-1, eta Isoform, ME-IV, 14-3-3, dapaf-1S, 14-3-3zeta Protein, immunoglobulin, apaf-1, dapaf-1L, B cell receptor accessory molecule complex, Brain 14 3 3 Protein, 14-3-3 Protein, 14-3-3 beta Protein, B lymphocyte receptor complex, B cell receptor activity, 14 3 3 gamma Protein, 14 3 3 eta Protein, PAP-A, dAPAF-1, PPDIV, abscisin II, GCPSfalseIP of 14-3-3 protein from Vicia GCP treated with ABAImmunoprecipitation of 14-3-3 protein using specific antibody against vf14-3-3a from Vicia GCPs treated with or without 10 µM ABA for 10 min in the dark.Thu Dec 16 00:00:00 GMT 2021PXD027058131567